HANSA BIOPHARMA

Interim Report

July 18, 2024

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Interim Results Conference Call Agenda

18 July 2024



CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Matt Shaulis Chief Commercial Officer
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Delivering on priorities across the business

STEADY COMMERCIAL MOMENTUM

3rd consecutive quarter of strong sales*

Year to Date	2Q 2024
94.6 MSEK *IDEFIRIX Sales*	**47.1 MSEK** *IDEFIRIX Sales*
74.7 MSEK *IDERIFIX Sales incl 19.9 MSEK provision*	**27.2 MSEK** *IDEFIRIX Sales incl 19.9 MSEK provision*
110.2 MSEK *Total Revenue*	**54.2 MSEK** *Total Revenue*

****Excluding impact of provision for discounts and sales adjustments***

NOTABLE PIPELINE PROGRESS

ConfIdeS fully randomized; data in 2H 2025

US ConfIdeS Phase 3 trial - fully randomized

Anti-GBM Phase 3 trial - 70% enrolled

PAES study - 70% enrolled

HNSA-5487 - on track to deliver further analysis of Ph 1 data in 2024

Interim Results Conference

18 July 2024



CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	**Matt Shaulis** **Chief Commercial Officer**
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

In-market growth and clinical utilization continue to drive IDEFIRIX® EU launch

- Reimbursement in 14 markets including 5 largest EU markets
- Access in 75% of EU transplant market

MARKET ACCESS

- 7 countries issued clinical guidelines
- **April ESOT consensus paper recommends imlifidase**
- 50 clinics are IDEFIRIX ready to treat

CLINICAL READINESS

- 28 centers with clinical experience
- First commercial sales in Italy
- Utilization in all major EU markets
- **60% of clinics have repeat use across 11 countries**
- **Five patients identified and treated in ET program**

PATIENT SELECTION AND TREATMENT

Advancing imlifidase's compelling profile in transplantation with additional trial data

Long-term follow-up study
17-HMedIdeS-14

Positive results of extended-pooled analysis from 17-HMedIdeS-14 and Phase 2 studies; will be published in a peer reviewed journal in 2024

PRESENTED AT ATC JUNE 2024

RESULTS
- **82% graft survival**
- **90% patient survival rate**
- **50 ml/min/m2 eGFR**



Included patients who consented to long-term follow-up and previously received imlifidase-enabled transplant in Phase 2 study

Post approval efficacy study (PAES)
20-HMedIdeS-19

Open label Phase 3 study to confirm the long-term efficacy and safety of IDEFIRIX

SUPPORT FULL EU MARKETING AUTHORIZATION

STATUS
- **36 out of 50 patients enrolled (72%)**
- **Expected completion in 2025**

Primary Endpoint
Determine one-year graft failure-free survival of the IDEFIRIX treated and transplanted patients

Secondary Endpoints (up to 1 year post transplant)
renal function; patient survival; graft survival

Additional RWE studies in France

US ConfIdeS trial is fully randomized; anticipated data read-out in 2H 2025

ABOUT CONFIDES

- Pivotal Phase 3 US trial
- Open-label, controlled, randomized trial evaluating 12-month kidney function in highly sensitized kidney transplant patients with positive crossmatch against a deceased donor
- Will compare desensitization using imlifidase with standard of care

STATUS

- 23 total centers in the trial; more than 140 patients consented
- 15 sites randomized two or more patients (65%)
- 13 trial sites have treated patients with imlifidase

Involved ConfIdeS sites cover more than 20% of total transplantation volumes in the U.S[1]

WHAT'S NEXT

1. 12 month follow up; data readout in 2H 2025
2. Planned BLA submission 2H 2025
3. Continued site level engagement

Interim Results Conference

18 July 2024



CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Matt Shaulis Chief Commercial Officer
Pipeline Update	**Hitto Kaufmann** **Chief R&D Officer**
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Key pipeline progress and a look ahead

	Progress to date	What's next 2H '24	Looking ahead - 2025
EARLY DEV	• **COMPLETED NICE-01 Ph 1** safety/tolerability for HNSA-5487	• **HNSA-5487 Ph 1** data on exploratory endpoints and clinical development path	• **HNSA-5487** clinical development
TRANSPLANT	• **FULL RANDOMIZATION ConfIdeS** Ph 3 trial	• **15-HMedIdeS-14** data publication in peer reviewed journal	• **ConfIdeS Ph 3** 12 month follow up and BLA submission in 2H • **Post Authorization Efficacy Study** readout
GENE THERAPY	• **STUDY INITIATED: SRP 9001-104** Ph 1 study (DMD) • Genethon (Crigler-Najjar) preclinical • AskBio (Pompe) preclinical	• **Genethon** trial to commence (Crigler-Najjar)	• **SRP 9001-104 Ph 1 study** (DMD) initial data readout
AUTOIMMUNE	• **TRIAL COMPLETED 15-MedIdeS-09 (GBS)** Ph 2 trial • **70% ENROLLED GOOD-IDES-12** Ph 3 (anti-GBM) trial	• **15-MedIdeS-09 Ph 2 (GBS)** data contextualization (IGOS) • **16-MedIdeS-12 Ph 2 (AMR)** data publ	• **GOOD-IDES-12 Ph 3 (anti-GBM)** 1H full enrolment; 2H data readout

Interim Results Conference

18 July 2024

CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Matt Shaulis Chief Commercial Officer
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	**Evan Ballantyne** **Chief Financial Officer**
Q&A and Close	Søren Tulstrup Chief Executive Officer, President

Strong commercial performance with total Q2 product sales of 47 MSEK offset by provision totaling 19.9 MSEK

Revenue (Q/Q)



Revenue (1H/1H)



Product Sales (Q/Q)



Product Sales Rolling (Last 12 months)



Continued investments in commercialization and R&D activities













Cash runway into 2026 through directed share issue









Interim Results Conference

18 July 2024



CEO Remarks	Søren Tulstrup Chief Executive Officer, President
Operational Update	Matt Shaulis Chief Commercial Officer
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Q&A and Close	**Søren Tulstrup** **Chief Executive Officer, President**

Hansa Biopharma contacts and key events

Contacts

Evan Ballantyne

Chief Financial Officer

Email: ir@hansabiopharma.com

Stephanie Kenney

VP, Global Corporate Affairs

E-mail: media@hansabiopharma.com

Calendar and events

2024

9 SEPT	HC Wainwright 26th Annual Global Investment Conference, NY
24 OCT	Q3 2024 (July-September) Report
18-19 NOV	SEB Healthcare Seminar, Stockholm

2025

6 FEB	Full-year 2024 (January – December) Report
17 APR	Q1 2025 (January – March) Report


HANSA®
BIOPHARMA